Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Stewart Bieler et al.|The Lancet|2023Cited by 264
Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosisSe Won Oh, Ho Jun Chin|BMC Nephrology|2013Cited by 59